C4 Therapeutics (CCCC) Competitors $1.84 -0.01 (-0.54%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.84 +0.00 (+0.27%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CCCC vs. KURA, VECT, ORIC, VERV, GHRS, VALN, TYRA, UPB, CGEM, and OPTShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Kura Oncology (KURA), VectivBio (VECT), ORIC Pharmaceuticals (ORIC), Verve Therapeutics (VERV), GH Research (GHRS), Valneva (VALN), Tyra Biosciences (TYRA), Upstream Bio (UPB), Cullinan Therapeutics (CGEM), and Opthea (OPT). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. Kura Oncology VectivBio ORIC Pharmaceuticals Verve Therapeutics GH Research Valneva Tyra Biosciences Upstream Bio Cullinan Therapeutics Opthea C4 Therapeutics (NASDAQ:CCCC) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability. Does the MarketBeat Community prefer CCCC or KURA? Kura Oncology received 407 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 69.55% of users gave Kura Oncology an outperform vote while only 38.57% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformC4 TherapeuticsOutperform Votes2738.57% Underperform Votes4361.43% Kura OncologyOutperform Votes43469.55% Underperform Votes19030.45% Which has more volatility and risk, CCCC or KURA? C4 Therapeutics has a beta of 2.99, meaning that its share price is 199% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Do analysts recommend CCCC or KURA? C4 Therapeutics currently has a consensus price target of $12.50, suggesting a potential upside of 579.35%. Kura Oncology has a consensus price target of $25.50, suggesting a potential upside of 257.14%. Given C4 Therapeutics' higher possible upside, equities research analysts plainly believe C4 Therapeutics is more favorable than Kura Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.92 Is CCCC or KURA more profitable? Kura Oncology has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-313.35% -42.45% -27.55% Kura Oncology N/A -44.09%-39.57% Do institutionals and insiders hold more shares of CCCC or KURA? 78.8% of C4 Therapeutics shares are owned by institutional investors. 8.6% of C4 Therapeutics shares are owned by insiders. Comparatively, 5.5% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher earnings and valuation, CCCC or KURA? C4 Therapeutics has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$35.58M3.67-$132.49M-$1.51-1.22Kura Oncology$53.88M10.70-$152.63M-$2.03-3.52 Does the media prefer CCCC or KURA? In the previous week, Kura Oncology had 10 more articles in the media than C4 Therapeutics. MarketBeat recorded 11 mentions for Kura Oncology and 1 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.87 beat Kura Oncology's score of 0.66 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Overall Sentiment C4 Therapeutics Very Positive Kura Oncology Positive SummaryC4 Therapeutics beats Kura Oncology on 10 of the 19 factors compared between the two stocks. Remove Ads Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$130.62M$3.04B$5.65B$8.06BDividend YieldN/A1.54%4.57%4.01%P/E Ratio-1.0829.2923.1419.03Price / Sales3.67436.17385.7893.17Price / CashN/A168.6838.1634.64Price / Book0.453.956.934.33Net Income-$132.49M-$71.95M$3.20B$247.06M7 Day Performance-13.21%-3.76%-2.30%-0.37%1 Month Performance-32.10%-10.33%2.86%-3.85%1 Year Performance-77.48%-27.15%10.66%1.27% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics2.606 of 5 stars$1.84-0.5%$12.50+579.3%-77.1%$130.62M$35.58M-1.08150KURAKura Oncology4.3102 of 5 stars$7.29+2.1%$25.50+249.8%-66.3%$588.70M$53.88M-3.09130Analyst UpgradeVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeORICORIC Pharmaceuticals4.1105 of 5 stars$7.91+1.5%$18.86+138.4%-53.3%$561.82MN/A-4.3580VERVVerve Therapeutics1.8444 of 5 stars$6.32+5.9%$25.50+303.5%-60.0%$561.19M$32.33M-2.57110Analyst ForecastGHRSGH Research2.5021 of 5 stars$10.65-3.2%$30.86+189.7%+14.4%$554.10MN/A-13.4810VALNValneva1.8479 of 5 stars$6.81+0.3%$17.00+149.6%-8.9%$553.39M$158.54M-52.38700Short Interest ↑Gap UpTYRATyra Biosciences2.2376 of 5 stars$10.74-6.6%$30.50+184.0%-40.7%$543.48MN/A-6.6720Upcoming EarningsNews CoverageUPBUpstream BioN/A$9.87+2.7%$56.50+472.4%N/A$529.44M$2.37M0.0038Positive NewsCGEMCullinan Therapeutics2.2088 of 5 stars$9.03+2.7%$32.86+263.9%-53.2%$528.37MN/A-3.1830OPTOpthea0.7079 of 5 stars$3.41+7.1%$12.00+252.4%-12.8%$524.07M$87,666.000.008Analyst DowngradeShort Interest ↑Analyst RevisionNews CoverageGap Up Remove Ads Related Companies and Tools Related Companies Kura Oncology Competitors VectivBio Competitors ORIC Pharmaceuticals Competitors Verve Therapeutics Competitors GH Research Competitors Valneva Competitors Tyra Biosciences Competitors Upstream Bio Competitors Cullinan Therapeutics Competitors Opthea Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CCCC) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CCCC Stock Free CCCC Stock Alerts